Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Pharma-Bio Serv

OTCPK:PBSV
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PBSV
OTCPK
$19M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm the United States, Europe, and Brazil markets. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
PBSV Share Price and Events
7 Day Returns
5.1%
OTCPK:PBSV
-0.1%
US Life Sciences
-2.8%
US Market
1 Year Returns
-23.1%
OTCPK:PBSV
-9%
US Life Sciences
-15.9%
US Market
PBSV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pharma-Bio Serv (PBSV) 5.1% -2.4% 7.2% -23.1% 18.6% -28.4%
US Life Sciences -0.1% -13.2% -17.8% -9% 56.7% 76.3%
US Market -2.8% -18.8% -24% -15.9% 2.8% 13.3%
1 Year Return vs Industry and Market
  • PBSV underperformed the Life Sciences industry which returned -9% over the past year.
  • PBSV underperformed the Market in United States of America which returned -15.9% over the past year.
Price Volatility
PBSV
Industry
5yr Volatility vs Market

Value

 Is Pharma-Bio Serv undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Pharma-Bio Serv to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Pharma-Bio Serv.

OTCPK:PBSV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2020-01-31) in USD $ .075000
Payout Ratio Company Filings (2020-01-31) 3915.8%
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:PBSV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.029 (1 + (1- 21%) (5.02%))
1.159
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.159 * 5.44%)
8.05%

Discounted Cash Flow Calculation for OTCPK:PBSV using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Pharma-Bio Serv is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

OTCPK:PBSV Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= $0.08 / (8.05% - 1.74%)
$0.69
OTCPK:PBSV Discount to Share Price
Calculation Result
Value per share (USD) From above. $0.69
Current discount Discount to share price of $0.83
= -1 x ($0.83 - $0.69) / $0.69
-19.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Pharma-Bio Serv is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pharma-Bio Serv's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pharma-Bio Serv's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:PBSV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2020-01-31) in USD $0.09
OTCPK:PBSV Share Price ** OTCPK (2020-04-02) in USD $0.83
United States of America Life Sciences Industry PE Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 27.61x
United States of America Market PE Ratio Median Figure of 2,947 Publicly-Listed Companies 12.21x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pharma-Bio Serv.

OTCPK:PBSV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:PBSV Share Price ÷ EPS (both in USD)

= 0.83 ÷ 0.09

8.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharma-Bio Serv is good value based on earnings compared to the US Life Sciences industry average.
  • Pharma-Bio Serv is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Pharma-Bio Serv's expected growth come at a high price?
Raw Data
OTCPK:PBSV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
United States of America Life Sciences Industry PEG Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 2.13x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.88x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Pharma-Bio Serv, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Pharma-Bio Serv's assets?
Raw Data
OTCPK:PBSV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2020-01-31) in USD $0.92
OTCPK:PBSV Share Price * OTCPK (2020-04-02) in USD $0.83
United States of America Life Sciences Industry PB Ratio Median Figure of 38 Publicly-Listed Life Sciences Companies 4.24x
United States of America Market PB Ratio Median Figure of 5,146 Publicly-Listed Companies 1.2x
OTCPK:PBSV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:PBSV Share Price ÷ Book Value per Share (both in USD)

= 0.83 ÷ 0.92

0.9x

* Primary Listing of Pharma-Bio Serv.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharma-Bio Serv is good value based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Pharma-Bio Serv's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Pharma-Bio Serv has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Pharma-Bio Serv expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.2%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Pharma-Bio Serv expected to grow at an attractive rate?
  • Unable to compare Pharma-Bio Serv's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Pharma-Bio Serv's earnings growth to the United States of America market average as no estimate data is available.
  • Pharma-Bio Serv's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:PBSV Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:PBSV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 10.2%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.9%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 6.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:PBSV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:PBSV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-10-31 26 1
2021-10-31 24 1
2020-10-31 21 1
2020-04-05
OTCPK:PBSV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2020-01-31 20 0 2
2019-10-31 20 -2 2
2019-07-31 20 -1 2
2019-04-30 20 2 2
2019-01-31 19 3 2
2018-10-31 18 4 -1
2018-07-31 13 3 -2
2018-04-30 13 0 -3
2018-01-31 13 0 -3
2017-10-31 13 -2 -1
2017-07-31 17 -1 -1
2017-04-30 17 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Pharma-Bio Serv is high growth as no earnings estimate data is available.
  • Pharma-Bio Serv's revenue is expected to grow by 10.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:PBSV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Pharma-Bio Serv Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:PBSV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-10-31
2021-10-31
2020-10-31
2020-04-05
OTCPK:PBSV Past Financials Data
Date (Data in USD Millions) EPS *
2020-01-31 0.09
2019-10-31 0.09
2019-07-31 0.09
2019-04-30 0.10
2019-01-31 0.07
2018-10-31 -0.05
2018-07-31 -0.07
2018-04-30 -0.11
2018-01-31 -0.12
2017-10-31 -0.03
2017-07-31 -0.06
2017-04-30 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Pharma-Bio Serv will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Pharma-Bio Serv's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pharma-Bio Serv has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Pharma-Bio Serv performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pharma-Bio Serv's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pharma-Bio Serv's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Pharma-Bio Serv's 1-year earnings growth exceeds its 5-year average (27.4% vs -7.8%)
  • Pharma-Bio Serv's earnings growth has exceeded the US Life Sciences industry average in the past year (27.4% vs 21.5%).
Earnings and Revenue History
Pharma-Bio Serv's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pharma-Bio Serv Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:PBSV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2020-01-31 19.55 2.14 4.48
2019-10-31 19.51 2.09 4.48
2019-07-31 20.36 2.11 4.76
2019-04-30 20.02 2.40 4.72
2019-01-31 18.64 1.68 4.67
2018-10-31 17.80 -1.26 4.60
2018-07-31 13.47 -1.67 3.96
2018-04-30 12.82 -2.55 3.91
2018-01-31 12.98 -2.87 4.21
2017-10-31 13.30 -0.78 4.66
2017-07-31 16.59 -1.38 5.43
2017-04-30 17.47 -1.35 5.85
2017-01-31 18.68 -0.99 5.92
2016-10-31 19.54 -0.26 5.87
2016-07-31 20.77 0.78 5.83
2016-04-30 22.09 1.36 5.84
2016-01-31 22.40 1.69 5.70
2015-10-31 23.38 1.62 5.70
2015-07-31 24.64 1.93 5.64
2015-04-30 25.30 2.07 5.56
2015-01-31 26.43 2.04 5.94
2014-10-31 27.56 2.41 6.11
2014-07-31 29.21 2.81 6.36
2014-04-30 30.73 3.46 6.33
2014-01-31 32.42 4.52 6.03
2013-10-31 33.06 4.91 5.76
2013-07-31 32.44 4.76 5.35
2013-04-30 31.74 4.79 4.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Pharma-Bio Serv has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Pharma-Bio Serv used its assets more efficiently than the US Life Sciences industry average last year based on Return on Assets.
  • Pharma-Bio Serv has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Pharma-Bio Serv's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pharma-Bio Serv has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Pharma-Bio Serv's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pharma-Bio Serv's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pharma-Bio Serv is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pharma-Bio Serv's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pharma-Bio Serv's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Pharma-Bio Serv has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pharma-Bio Serv Company Filings, last reported 2 months ago.

OTCPK:PBSV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2020-01-31 21.13 0.00 15.25
2019-10-31 20.61 0.00 15.49
2019-07-31 21.79 0.00 14.80
2019-04-30 21.36 0.00 15.43
2019-01-31 20.69 0.00 15.80
2018-10-31 20.26 0.00 16.07
2018-07-31 18.72 0.00 15.23
2018-04-30 18.02 0.00 13.02
2018-01-31 18.17 0.00 13.20
2017-10-31 20.75 0.00 11.62
2017-07-31 21.04 0.00 12.23
2017-04-30 21.14 0.00 12.73
2017-01-31 21.45 0.00 13.69
2016-10-31 21.81 0.00 13.79
2016-07-31 22.31 0.00 14.04
2016-04-30 22.42 0.00 14.45
2016-01-31 22.30 0.00 14.54
2015-10-31 21.96 0.00 14.93
2015-07-31 21.50 0.00 14.04
2015-04-30 21.05 0.00 14.45
2015-01-31 20.68 0.00 15.11
2014-10-31 20.51 0.00 15.16
2014-07-31 19.66 0.00 13.86
2014-04-30 19.08 0.00 12.90
2014-01-31 18.74 0.00 13.85
2013-10-31 18.05 0.00 12.12
2013-07-31 16.78 0.00 9.19
2013-04-30 15.49 0.00 8.59
  • Pharma-Bio Serv has no debt.
  • Pharma-Bio Serv had no debt 5 years ago.
  • Pharma-Bio Serv has no debt, it does not need to be covered by operating cash flow.
  • Pharma-Bio Serv has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Pharma-Bio Serv's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pharma-Bio Serv has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Pharma-Bio Serv's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
9.04%
Current annual income from Pharma-Bio Serv dividends.
If you bought $2,000 of Pharma-Bio Serv shares you are expected to receive $181 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Pharma-Bio Serv's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (2.07%).
  • Pharma-Bio Serv's dividend is above the markets top 25% of dividend payers in United States of America (5.82%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:PBSV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1936 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2.1%
United States of America Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:PBSV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-10-31
2021-10-31
2020-10-31
2020-04-05
OTCPK:PBSV Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-10-28 0.075 9.336

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • It is too early to tell whether Pharma-Bio Serv has stable dividend payments.
  • Pharma-Bio Serv only just started paying a dividend, it is too early to tell if payments are increasing.
Current Payout to shareholders
What portion of Pharma-Bio Serv's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Pharma-Bio Serv has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Pharma-Bio Serv's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pharma-Bio Serv afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pharma-Bio Serv has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Pharma-Bio Serv's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Victor Sanchez
COMPENSATION $235,550
AGE 48
TENURE AS CEO 5.3 years
CEO Bio

Mr. Victor Sanchez has been the Chief Executive Officer and President at Pharma-Bio Serv, Inc. since January 1, 2015 and also has been its President of the European Operations since January 1, 2011. Mr. Sanchez served as an Operations Manager in the LOCM and OSD divisions of Merck Sharp & Dohme ( MSD), a pharmaceutical company, in Madrid, Spain from April 2010 to January 2011 and as an Operations Manager of the LOCM division of Schering-Plough S.A., a pharmaceutical company, in Madrid, Spain, from September 2004 to April 2010. He served as Quality Control Validations Manager for Schering-Plough Products, LLC, a pharmaceutical company ( Schering-Plough), in Puerto Rico from December 2000 to August 2004 and as Quality Control Laboratory Supervisor of Schering-Plough from April 1996 to December 2000. Mr. Sanchez holds a Bachelor of Science in Chemistry, summa cum laude and a M.B.A. in Industrial Management, cum laude, from the Interamerican University of Puerto Rico. He holds a Post Graduate Diploma in Pharmaceutical Validation Technology from the Dublin Institute of Technology, Ireland. Mr. Sanchez is a licensed Chemist by the Puerto Rico State Department and a Member of the American Chemical Society, the Parenteral Drug Association, the Regulatory Affairs Professional Society and the International Society for Pharmaceutical Engineers.

CEO Compensation
  • Victor's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Victor's remuneration is lower than average for companies of similar size in United States of America.
Management Team

Elizabeth Plaza

TITLE
Founder
COMPENSATION
$540K
AGE
55

Victor Sanchez

TITLE
CEO, President & President of European Operations
COMPENSATION
$236K
AGE
48
TENURE
5.3 yrs

Pedro Lasanta

TITLE
CFO, VP of Finance & Administration and Secretary
COMPENSATION
$235K
AGE
59
TENURE
12.4 yrs
Board of Directors Tenure

Average tenure and age of the Pharma-Bio Serv board of directors in years:

14.3
Average Tenure
63
Average Age
  • The average tenure for the Pharma-Bio Serv board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Elizabeth Plaza

TITLE
Founder
COMPENSATION
$540K
AGE
55
TENURE
14.3 yrs

Howie Spindel

TITLE
Independent Director
COMPENSATION
$51K
AGE
74
TENURE
14.3 yrs

Dov Perlysky

TITLE
Independent Director
COMPENSATION
$51K
AGE
57
TENURE
16.3 yrs

Kirk Michel

TITLE
Independent Director
COMPENSATION
$51K
AGE
63
TENURE
14.3 yrs

Irving Wiesen

TITLE
Independent Director
COMPENSATION
$51K
AGE
64
TENURE
14.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Pharma-Bio Serv's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pharma-Bio Serv has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm the United States, Europe, and Brazil markets. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil. The company’s technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

Details
Name: Pharma-Bio Serv, Inc.
PBSV
Exchange: OTCPK
Founded: 1993
$19,091,350
23,001,627
Website: http://www.pharmabioserv.com
Address: Pharma-Bio Serv, Inc.
Pharma-Bio Serv Building,
Suite 6,
Dorado,
Puerto Rico, 00646,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK PBSV Common Stock Pink Sheets LLC US USD 04. Dec 2006
Number of employees
Current staff
Staff numbers
185
Pharma-Bio Serv employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 04:34
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/01/29
Last earnings filing: 2020/03/16
Last earnings reported: 2020/01/31
Last annual earnings reported: 2019/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.